Clinical effect of combination of lactulose and Bifid-triple viable capsule on spontaneous bacterial peritonitis with hepatic cirrhosis

Objective To explore the clinical effect of combination of lactulose and Bifid-triple viable capsule on spontaneous bacterial peritonitis(SBP) with hepatic cirrhosis.Methods 186 cases of decompensated hepatic cirrhosis were randomly divided into lactulose and Bifid-triple viable capsule combination group(n = 93) and conventional antibiotic treatment group(n = 93).During hospitalization,all patients were treated with diuretics and supportive treatment.The clinical effect was observed after three months.In addition,the ascites was collected for TNF-α and IL-6 detection using ELISA.Results The incidence of SBP in lactulose and Bifid-triple viable capsule combination group was 12.9%,while that in conventional antibiotic therapy group reached to 21.5%,which showed significant difference(P 0.05).The concentration of TNF-α was(1650 ± 126) pg / mL in ascites with SBP while(1312 ± 289) pg / mL in ascites without SBP,with a significant difference(P 0.05).The concentration of IL-6 was(2566 ± 138) pg / mL in ascites with SBP while(924 ±251) pg/mL in ascites without SBP,with a significant difference(P 0.05).Conclusion The combination of lactulose and Bifid-triple viable capsule could reduce the incidence of SBP significantly.The levels of TNF-α and IL-6 in ascites could be used to monitor the occurrence of SBP in patients with cirrhosis.